Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post Hoc Analysis of a Randomized Trial
| Autor: | Beverly Orsak, Joan Hecht, Fernando Bril, Fermin O. Tio, Romina Lomonaco, Paola Portillo Sanchez, Kenneth Cusi |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Male
Magnetic Resonance Spectroscopy endocrine system diseases Endocrinology Diabetes and Metabolism Clinical Biochemistry Biochemistry Liver disease 0302 clinical medicine Endocrinology Non-alcoholic Fatty Liver Disease Nonalcoholic fatty liver disease 030212 general & internal medicine Prediabetes education.field_of_study food and beverages Alanine Transaminase Middle Aged Liver Cardiovascular Diseases Female lipids (amino acids peptides and proteins) 030211 gastroenterology & hepatology medicine.drug medicine.medical_specialty Statin medicine.drug_class Population Prediabetic State 03 medical and health sciences Insulin resistance Internal medicine Diabetes mellitus medicine Humans Hypoglycemic Agents Aspartate Aminotransferases cardiovascular diseases education Clinical Research Articles Dyslipidemias Pioglitazone business.industry Biochemistry (medical) nutritional and metabolic diseases medicine.disease Surgery Diabetes Mellitus Type 2 Glucose Clamp Technique Thiazolidinediones Hydroxymethylglutaryl-CoA Reductase Inhibitors business |
| Zdroj: | The Journal of Clinical Endocrinology & Metabolism. 102:2950-2961 |
| ISSN: | 1945-7197 0021-972X |
| DOI: | 10.1210/jc.2017-00867 |
| Popis: | Context Patients with nonalcoholic fatty liver disease have a high cardiovascular risk, but statins are rarely prescribed because of fear of hepatotoxicity. Objective To prospectively assess the long-term safety of statins in patients with prediabetes/type 2 diabetes mellitus (T2DM) and nonalcoholic steatohepatitis (NASH). Design Post hoc analysis of statin use during a randomized, controlled trial assessing pioglitazone vs placebo for NASH. Patients A total of 101 patients (86 receiving statins) with biopsy-proven NASH and prediabetes/T2DM were followed for up to 36 months. Interventions Oral glucose tolerance test and percutaneous liver biopsy (baseline, month 18, and month 36); liver magnetic resonance spectroscopy and euglycemic insulin clamp (baseline and month 18). Main outcome measures Histologic and biochemical safety of statin use among patients with NASH. Results Only 37% of patients were receiving statins at enrollment despite their high cardiovascular risk. Statin nonusers had higher plasma alanine aminotransferase levels but similar histologic severity of liver disease at baseline. In both statin users and nonusers, the same number of patients (n = 4) had a twofold or greater increase in plasma aminotransferases during follow-up. One statin nonuser was discontinued from the study because of this elevation. Values returned to normal without any active measure in all other cases. No changes on liver histology or hepatic insulin resistance were observed in patients with NASH newly started on a statin and receiving placebo during the main study. Conclusions Statin therapy is safe in patients with prediabetes/T2DM and NASH. Given their high cardiovascular risk, statin therapy should be encouraged in this population. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|